Interpace Biosciences, Inc.II

Interpace Biosciences, Inc.

1.25USDD
0.000.00%
As of today at 18:09 GMT
USD
No trades
See on Supercharts

IDXG fundamentals

Key facts

Market capitalization‪5.51 M‬USD
Founded1986
CEOThomas W. Burnell
About

Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test, ThyGenX, an expanded oncogenic mutation panel that helps identify malignant thyroid nodules, ThyraMIR, which assesses thyroid nodules for risk of malignancy, and RespriDx, a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. The company was founded by John P. Dugan in 1986 and is headquartered in Parsippany, NJ.

Ownership
‪‪4.40 M‬‬
Free Float shares
‪‪3.30 M‬‬ (74.82%)
Closely held shares
‪‪1.11 M‬‬ (25.18%)
Free Float shares
‪‪3.30 M‬‬ (74.82%)
Closely held shares
‪‪1.11 M‬‬ (25.18%)
Capital structure
Market cap
‪‪5.51 M‬‬
Debt
‪‪7.18 M‬‬
Preferred stock
‪‪46.54 M‬‬
Cash & equivalents
‪‪2.11 M‬‬
Enterprise value
‪‪57.11 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪5.51 M‬‬
Price to earning ratio (P/E)
1.17x
Price to sales ratio (P/S)
0.12x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
1.17x
Price to sales ratio (P/S)
0.12x
Valuation ratios
‪0.00‬
‪0.05‬
‪0.10‬
‪0.15‬
‪0.20‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪2.00‬
‪4.00‬
‪6.00‬
‪8.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−6%‬
‪0%‬
‪6%‬
‪12%‬
‪18%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−4.50 M‬‬
‪0.00‬
‪‪4.50 M‬‬
‪‪9.00 M‬‬
‪‪13.50 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪3.50 M‬‬
‪‪7.00 M‬‬
‪‪10.50 M‬‬
‪‪14.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪3.50 M‬‬
‪‪7.00 M‬‬
‪‪10.50 M‬‬
‪‪14.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Diagnostic Clinical Services
By country
Period: 2023
United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪4.00 M‬‬
‪‪8.00 M‬‬
‪‪12.00 M‬‬
‪‪16.00 M‬‬
Estimate
Earnings
Next:Mar 26, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪0.03‬
‪0.06‬
‪0.09‬
‪0.12‬
Estimate

Dividends

Dividend yield, history and sustainability

IDXG does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−5.00 M‬‬
‪0.00‬
‪‪5.00 M‬‬
‪‪10.00 M‬‬
‪‪15.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪5.00 M‬‬
‪‪10.00 M‬‬
‪‪15.00 M‬‬
‪‪20.00 M‬‬
Assets
Liabilities